← All trials
NCT05186129
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 6, 2018
- Primary completion
- Apr 15, 2018
- Completion date
- Apr 20, 2018
- First posted
- Jan 11, 2022
- Last posted
- Mar 2, 2022
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KarachiLead sponsor
- Ferozsons Laboratories Ltd.Collaborator
- University of KarachiOverall official - principal investigator
- University of KarachiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.